Skip to content
Review Open access

Targeting mitochondrial dysfunction with traditional Chinese medicine for inflammatory bowel disease: a comprehensive review

Jul 2026 · Frontiers in Pharmacology · Vol 17 · 0 citations · 180 references
Medicine

TL;DR

Current research on how active metabolites of TCM modulate mitochondrial dysfunction in the prevention and treatment of IBD is summarized, providing new insights into the pathogenesis of the disease and opening up new avenues and strategies for the prevention, treatment, and research on IBD treatment with TCM.

Abstract

Inflammatory Bowel Disease (IBD) is a chronic relapsing inflammatory condition of the intestine, characterized by symptoms such as chronic diarrhea, abdominal pain, and weight loss. The pathogenesis of IBD is complex, with mitochondrial dysfunction being considered a key factor in its onset, progression, and persistence. Mitochondria, as the primary energy suppliers within cells, not only produce adenosine triphosphate (ATP) but also play crucial roles in regulating cellular metabolism, maintaining redox balance, and controlling cell death processes. Targeting mitochondria to regulate mitochondrial functions, including energy metabolism, oxidative stress, mitophagy, dynamics, and biogenesis, as well as maintaining the dynamic balance of the “gut microbiota-mitochondria axis,” has emerged as a promising strategy for the prevention and treatment of IBD. Traditional Chinese Medicine (TCM) has shown potential multi-target regulatory properties in preclinical studies; however, robust clinical validation and target-specific pharmacological evidence remain limited. This review explores the mechanisms and underlying connections between mitochondrial dysfunction and IBD, summarizing the current research on how active metabolites of TCM modulate mitochondrial dysfunction in the prevention and treatment of IBD. It provides new insights into the pathogenesis of the disease and opens up new avenues and strategies for the prevention, treatment, and research on IBD treatment with TCM.

Read PDF

Similar papers

Review Open access Jul 2026

Regulation of ferroptosis and mitochondrial homeostasis disruption in diabetic cardiomyopathy: Therapeutic potential of traditional Chinese medicine

Given the multifactorial nature of DCM, combination therapies targeting ferroptosis and mitochondrial dysfunction may offer superior outcomes, and future drug development should prioritize agents that precisely regulate these interrelated pathways, enabling personalized treatment strategies for DCM.

Yiting Tang, Qian Wu, Yu-Peng Chen et al. · 0 citations
Review Aug 2026

Modulating the gut microbiota: a multi-target mechanism of traditional Chinese medicine for type 2 diabetes management.

A path forward is proposed for integrating microbiota-targeted TCM therapies into the modern, evidence-based management of T2DM, highlighting both therapeutic potential and current challenges, such as the need for standardization.

Zhiping Ding, Qunfang Li, Z. Li et al. · 0 citations
Review Sep 2026

Mitochondria-targeted natural products with potential for the treatment of mitochondria-related diseases.

This review systematically summarize the specific mitochondrial pathological phenotypes in various diseases and provides a comprehensive overview of natural products that correspond to these phenotypes, along with their mechanisms of action.

Xin-Yue Liu, Hu Li, Xuekai Wang et al. · 0 citations
Review Open access Aug 2026

Cancer Cachexia Research and Drug Development: Lessons from Failures and the Promise of Immunomodulation

This review summarizes the progression of cachexia research, highlighting key findings involving inflammatory cytokines, proteolytic pathways, mitochondrial dysfunction, and immune dysregulation, and novel immunomodulatory strategies, including R-ketorolac, which may restore immune homeostasis and target the root cause...

Ling-Bing Zhang, Jeffrey A. Norton · 0 citations
Review Aug 2026

Mitochondrial guardian and therapeutic target: The promise of TFAM in acute kidney injury.

Evidence showing that TFAM upregulation, whether through pharmacological interventions or genetic manipulation, consistently protects against tubular cell injury, preserves mitochondrial function, and attenuates inflammation across diverse AKI models is integrated.

Luyao Zhang, Zi-Yi Yang, Rushuang Yue et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.